Abstract
Type 2 diabetes (T2D) has been considered a relentlessly worsening disease, due to the progressive deterioration of the pancreatic beta cell functional mass. Evidence indicates that remission of T2D may occur in variable proportions of patients after specific treatments that are associated with recovery of beta cell function. The recovery of beta cells has been shown in human islets obtained from non-diabetic organ donors that recover from “lipo-glucotoxic” conditions, and human islets isolated from T2D organ donors exposed to specific treatments or by a period of exposure to a “non-diabetic” milieu. The improvement of insulin secretion and the associated molecular traits unveil the possibility to promote T2D remission by directly targeting pancreatic beta cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
